Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.

Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT.

Am J Transplant. 2013 Jun;13(6):1601-5. doi: 10.1111/ajt.12209.

2.

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.

Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M.

Liver Transpl. 2012 Sep;18(9):1053-9. doi: 10.1002/lt.23482.

3.

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.

Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M.

Dig Liver Dis. 2014 Oct;46(10):923-7. doi: 10.1016/j.dld.2014.06.004.

PMID:
24997638
4.
5.

Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.

Kim B, Trivedi A, Thung SN, Grewal P.

Semin Liver Dis. 2014 Feb;34(1):108-12. doi: 10.1055/s-0034-1371084.

PMID:
24782264
6.

Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.

Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, Botta D, Durand F, Silvain C, Lebray P, Houssel-Debry P, Kamar N, D'Alteroche L, Petrov-Sanchez V, Diallo A, Pageaux GP, Duclos-Vallee JC; Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO23 Compassionate Use of Protease Inhibitors in Viral C in Liver Transplantation Study Group..

Clin Gastroenterol Hepatol. 2015 Nov;13(11):1993-2001.e1-2. doi: 10.1016/j.cgh.2015.05.030.

PMID:
26044317
7.

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR.

Liver Transpl. 2004 Feb;10(2):199-207.

8.

A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir.

Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G.

Curr Med Chem. 2013;20(30):3733-42. Review.

PMID:
23848533
9.

Chronic hepatitis C virus infection in renal transplant: treatment and outcome.

Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.

Clin Transplant. 2006 Nov-Dec;20(6):677-83.

PMID:
17100715
10.

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.

Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt-Sarif T, Chang P, Kivett V, Castells L, Prieto M, Fontana RJ, Baumert TF, Coilly A, Londoño MC, Habersetzer F.

Hepatology. 2015 May;61(5):1485-94. doi: 10.1002/hep.27681.

11.

Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.

Herzer K, Papadopoulos-Köhn A, Walker A, Achterfeld A, Paul A, Canbay A, Timm J, Gerken G.

Digestion. 2015;91(4):326-33. doi: 10.1159/000382075.

PMID:
25999053
12.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
13.
14.

Hepatitis C genotypes in liver transplant recipients: distribution and 1-year follow-up.

Zein NN, Rakela J, Poterucha JJ, Steers JL, Wiesner RH, Persing DH.

Liver Transpl Surg. 1995 Nov;1(6):354-7.

15.

A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.

Uyama H, Enomoto H, Kishima Y, Yamamoto M, Yoshida K, Okuda Y, Hirotani T, Kuroda T, Ito H, Matsuda M, Terabayashi M, Noguchi S, Kawase I, Nakamura H.

Hepatogastroenterology. 2003 Nov-Dec;50(54):2112-6.

PMID:
14696476
16.

To transplant or not to transplant recurrent hepatitis C and liver failure.

Forman LM.

Clin Liver Dis. 2003 Aug;7(3):615-29. Review.

PMID:
14509530
17.

Evolution of hepatitis C virus in liver allografts.

Demetris AJ.

Liver Transpl. 2009 Nov;15 Suppl 2:S35-41. doi: 10.1002/lt.21890.

18.

New modalities in the treatment of HCV in pre and post - transplantation setting.

Araz F, Durand CM, Gürakar A.

Turk J Gastroenterol. 2015 May;26(3):204-13. doi: 10.5152/tjg.2015.0204. Review.

19.

Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation.

De Vera ME, Smallwood GA, Rosado K, Davis L, Martinez E, Sharma S, Stieber AC, Heffron TG.

Transplantation. 2001 Mar 15;71(5):678-86.

PMID:
11292302
20.

Supplemental Content

Support Center